Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

(2012) Daniel Keizman et al.   EUROPEAN JOURNAL OF CANCER

The Epidemiology of Renal Cell Carcinoma

(2011) Börje Ljungberg et al.   EUROPEAN UROLOGY

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

(2011) David H. Henry et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence

(2011) T. E. Hutson   ONCOLOGIST

Skeletal complications and survival in renal cancer patients with bone metastases

(2010) Emma Woodward et al.   BONE

Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy

(2010) Daniel Y. C. Heng et al.   CANCER

Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer

(2010) Fred Saad et al.   SEMINARS IN ONCOLOGY

Safety Considerations for Use of Bone-Targeted Agents in Patients With Cancer

(2010) Joanne E. Mortimer et al.   SEMINARS IN ONCOLOGY

Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms

(2009) Peter Mulders   BJU INTERNATIONAL

Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity

(2009) Pierre P Major et al.   BMC CANCER

Prognostic Factors and Survival of Renal Clear Cell Carcinoma Patients with Bone Metastases

(2009) Attila Szendrői et al.   PATHOLOGY & ONCOLOGY RESEARCH